Weight-Loss drug plus IUD aimed to save uteruses – but trial never started

NCT ID NCT05829460

Terminated Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test whether combining the weight-loss drug semaglutide with a hormone-releasing IUD could reverse endometrial hyperplasia (a precancerous condition) in premenopausal women with obesity, allowing them to keep their uterus. The trial was withdrawn before enrolling any participants, so no data were collected. The approach remains untested.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (a GLP-1 receptor agonist) and a levonorgestrel-releasing intrauterine device (IUD)
What this could lead to: If it had worked, this combination could have offered a non-surgical way to reverse endometrial hyperplasia and preserve the uterus in women with obesity.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. It is unclear if the approach would have been effective or safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMPLEX ATYPICAL ENDOMETRIAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical endometrial hyperplasia Endometrial Hyperplasia endometrial hyperplasia without atypia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL HYPERPLASIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.